<DOC>
	<DOCNO>NCT00004016</DOCNO>
	<brief_summary>RATIONALE : Interferon gamma may interfere growth cancer cell may effective treatment melanoma solid tumor . PURPOSE : Phase I trial study effectiveness interferon gamma treat patient recurrent metastatic melanoma solid tumor .</brief_summary>
	<brief_title>Interferon Gamma Treating Patients With Recurrent Metastatic Melanoma Other Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intratumoral adenovirus vector contain interferon gamma patient locally recurrent metastatic melanoma solid tumor . II . Assess safety tolerability regimen patient population . III . Determine local distant antitumor effect regimen patient . IV . Evaluate biological immunological effect regimen extent local interferon gamma expression patient . OUTLINE : This dose escalation study . Patients receive adenovirus interferon gamma intratumorally day 1 , 8 , 15 . Patients achieve tumoral response may receive additional course therapy discretion investigator . Cohorts least 3 patient receive escalate dos adenovirus interferon gamma maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . Patients follow 3 week treatment . PROJECTED ACCRUAL : A minimum 12 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma solid tumor amenable curative therapy Locally recurrent OR Metastatic disease Suitable cutaneous nodal sit intratumoral injection No uncontrolled CNS metastasis Brain metastasis allow stereotactically surgically treat , well control , require systemic corticosteroid PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 10.0 g/dL WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGPT/SGOT great 3 time ULN Renal : Creatinine great 2 time ULN Other : HIV negative No active systemic infection No serious systemic medical condition Positive delay hypersensitivity reaction least one follow antigen : tetanus , candida , mumps , trichophyton Not pregnant Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy melanoma No concurrent immunotherapy Chemotherapy : At least 3 week since prior systemic chemotherapy melanoma No concurrent chemotherapy Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>